















SPOTLIGHT ON MPTs ADDRESSING STIs

	Preclinical	Phase I	Phase II	Phase III
HIV + other STIs				
HIV, Gonorrhea				
HIV, HPV				
HIV, HPV, HSV				
HIV, HSV				
HIV, BV				
HIV, HSV, HPV, BV				
HIV + other STIs + Contraceptives				
HIV, HSV, Pregnancy				
HIV, HSV, HPV, Pregnancy				
HIV, HSV, Chlamydia, Gonorrhea, Pregnancy				
HIV, HSV, BV, Chlamydia, Gonorrhea, Pregnancy				
Other STIs + Contraceptives				
HSV, Zika ² , Pregnancy				

HIV + other STIs + Contraception

8

HIV + other STIs

8

Contraception + other STIs

1

¹ Bacterial vaginosis (BV) is not sexually transmitted but can be linked to sexual activity. While BV is not an STI, it has been included here for consistency.

² The Zika virus can be transmitted through sexual contact and lead to pregnancy complications and congenital defects. It is included here for its adverse effects on sexual and reproductive health.

For more information about STI trials, please visit stiwatch.org

Adapted from: *The Initiative for MPTs (IMPT) Product Development Database; Treatment Action Group (TAG) 2023 Pipeline Report; MATRIX R&D Landscape Review 2024.*